

A comparison of transcutaneous, end-tidal and arterial measurements of carbon dioxide during general anaesthesia

Craig W. Reid MD, Raymond J. Martineau MD,
Donald R. Miller MD, Kathryn A. Hull RN,
John Baines BSc, Patrick J. Sullivan MD

A randomized, prospective study was performed to evaluate the accuracy of a new transcutaneous carbon dioxide (CO₂) monitor (Fastrac[®]) during general anaesthesia. Twenty-two adult patients undergoing elective surgery were subjected to three different levels of minute ventilation by varying their respiratory rates in a randomized cross-over design. Simultaneous measurements of transcutaneous CO₂ (P_{tc}CO₂) and arterial CO₂ (PaCO₂) were obtained at three levels of minute ventilation (low, medium and high). End-tidal CO₂ (P_{ET}CO₂) values were also recorded from a mass spectrometer (SARA[®]) at each time period. A total of 66 data sets with PaCO₂ ranging from 28–62 mmHg were analyzed. The P_{tc}CO₂ values demonstrated a high degree of correlation with PaCO₂ over the range of minute ventilation ($y = 0.904x + 6.36$, $r = 0.92$, $P < 0.001$). The P_{ET}CO₂ measurement also demonstrated a generally good correlation with PaCO₂ ($y = 0.62x + 9.21$, $r = 0.89$, and $P < 0.01$). However, the P_{ET}CO₂-PaCO₂ gradients (mean 7.0 ± 3.1 mmHg) were greater than the P_{tc}CO₂-PaCO₂ gradients (mean

2.3 ± 2.4 mmHg) at all three levels of minute ventilation ($P < 0.05$). These differences were greatest when PaCO₂ was in the high range (48–60 mmHg). We conclude that the new Fastrac[®] CO₂ monitor is accurate for monitoring carbon dioxide levels during general anaesthesia. The new transcutaneous devices provide an effective method for non-invasive monitoring of CO₂ in situations where continuous, precise control of CO₂ levels is desired.

Une étude prospective randomisée fut entreprise afin d'évaluer durant l'anesthésie générale un nouveau moniteur transcutané de CO₂ (Fastrac[®]). Vingt-deux patients adultes subissant une chirurgie électorive ont subi trois différents niveaux de ventilation minute en variant la fréquence d'une façon randomisée avec entrecroisement. Les mesures simultanées de la CO₂ transcutanée (P_{tc}CO₂) et la CO₂ artérielle (PaCO₂) furent obtenues à trois niveaux de ventilation minute (bas, moyen et élevé). Les valeurs de la CO₂ en fin d'expiration (P_{ET}CO₂) furent aussi enregistrées par un spectromètre de masse (SARA[®]) à chaque période. Un total de 66 ensembles de données avec des PaCO₂ variant de 28–62 mmHg furent analysées. Les valeurs de P_{tc}CO₂ ont démontré un haut degré de corrélation avec la PaCO₂ pour ces valeurs de ventilation minute ($y = 0,904x + 6,36$, $r = 0,92$, $P < 0,001$). Les mesures de la P_{ET}CO₂ ont aussi démontré une bonne corrélation avec la PaCO₂ ($y = 0,62x + 9,21$, $r = 0,89$, et $P < 0,01$). Cependant, les gradients de P_{ET}CO₂-PaCO₂ (moyenne $7,0 \pm 3,1$ mmHg) furent plus grands que les gradients de P_{tc}CO₂-PaCO₂ (moyenne $2,3 \pm 2,4$ mmHg) aux trois valeurs de ventilation minute étudiées ($P < 0,05$). Ces différences étaient plus élevées quand la PaCO₂ était maintenue à des niveaux élevés (48–60 mmHg). On conclut que le nouveau moniteur de CO₂ Fastrac[®] est précis pour la surveillance du niveau du CO₂ durant l'anesthésie générale. Ces nouveaux appareils transcutanés fournissent une méthode efficace pour la surveillance non-invasive de la CO₂ dans des situations où un contrôle continu et précis du niveau de CO₂ est désiré.

Key words

CARBON DIOXIDE: monitoring;
TENSION: arterial, cutaneous, end-tidal, gradients;
MONITORING: carbon dioxide;
VENTILATION: carbon dioxide tension.

From the Departments of Anaesthesia and Biomedical Engineering, Ottawa General Hospital and The University of Ottawa, Ottawa, Ontario.

Presented at the Annual Meeting of The Canadian Anaesthetists' Society, Vancouver, June, 1990.

Supported in part by a research grant from Johnson and Johnson (Medical Products) Inc.

Address correspondence to: Dr. Donald R. Miller, Department of Anaesthesia, Ottawa General Hospital, 501 Smyth Road, Ottawa, Ontario K1H 8L6.

Accepted for publication 29th August, 1991.

In order to monitor the adequacy of alveolar ventilation, it is now standard practice to have a continuous estimate of arterial carbon dioxide (PaCO_2) for all patients undergoing general anaesthesia. Continuous measurement of end-tidal carbon dioxide partial pressure (PETCO_2) by either mass spectrometry or infrared capnometry has become the most widely used method for measuring CO_2 concentrations of the end-tidal respiratory gases. The PETCO_2 is used to reflect arterial PaCO_2 levels, assuming a normal PETCO_2 - PaCO_2 gradient.¹⁻³ However, this method of estimating arterial PaCO_2 is sometimes inaccurate in clinical practice, as a result of influences by pathologic processes which increase the PETCO_2 - PaCO_2 gradient. This includes diseases which increase pulmonary dead space, and to a lesser extent, diseases which cause ventilation-perfusion mismatching or pulmonary shunting.⁴⁻⁶ This concern prompted the current investigators to evaluate the accuracy of a new transcutaneous carbon dioxide (PtcCO_2) monitor with a dual sensing electrode, as an additional method of CO_2 measurement.

Recent technological advances have led to the development of several PtcCO_2 monitors which are considerably smaller and easier to operate than the early prototypes. Additional advances include improved calibration, and the development of a dual sensing electrode which can measure oxygen and carbon dioxide levels simultaneously. The transcutaneous monitor provides an estimate of PaCO_2 by non-invasive sampling from "arterialized" capillary blood, a process which is not influenced by abnormalities in pulmonary gas exchange.^{7,8} The transcutaneous CO_2 monitor may therefore provide a closer approximation of PaCO_2 than does capnography.

The purpose of this prospective, randomized study was to examine the potential clinical utility of PtcCO_2 monitoring during general anaesthesia by evaluating the accuracy of the most recently commercially available transcutaneous monitor (Fastrac[®]). A secondary aim was to compare transcutaneous-arterial and end-tidal-arterial CO_2 gradients at different levels of minute ventilation. A healthy patient population was selected for this initial validation.

Methods

Patient population

Twenty-two ASA physical status I or II patients who were scheduled to undergo elective surgery under general anaesthesia in the supine position were enrolled in the study. All patients gave written, informed consent to the protocol which had been approved by the Hospital Human Experimental Procedures Committee. Excluded were patients greater than 60 yr of age, those with a history of smoking more than ten pack-years, asthmatics, individuals

with COPD, and patients who were either obese or pregnant.

Anaesthetic management

Patients received premedication with oral diazepam, $0.15 \text{ mg} \cdot \text{kg}^{-1}$ given 90 min preoperatively. In the operating room, intravenous access was established, and an ECG, non-invasive blood pressure monitor, and pulse oximeter were applied. Induction of anaesthesia was performed with fentanyl $2-4 \mu\text{g} \cdot \text{kg}^{-1}$, thiopentone $4-5 \text{ mg} \cdot \text{kg}^{-1}$ and an appropriate muscle relaxant. Following tracheal intubation, inspired and end-tidal concentrations of oxygen, carbon dioxide, and anaesthetic gases were monitored with an on-line mass spectrometer (SARA, PPG). Maintenance of anaesthesia consisted of nitrous oxide and oxygen in a 2:1 ratio, isoflurane (0.25–1.5% end-tidal), and incremental boluses of either fentanyl or alfentanil as required to maintain an appropriate depth of anaesthesia, as determined by the attending staff physician. Upon completion of surgery, inhalational agents were discontinued, residual neuromuscular blockade was reversed, and extubation was performed after patients had been breathing 100% oxygen for several minutes.

Protocol

The lungs were mechanically ventilated with a tidal volume of $8-10 \text{ ml} \cdot \text{kg}^{-1}$ and a total fresh gas flow rate (FGF) of $3.0 \text{ L} \cdot \text{min}^{-1}$, delivered from a circle breathing system with a carbon dioxide absorber. Once a stable level of anaesthesia had been achieved, each patient was subjected to three different levels of minute ventilation in a randomized cross-over design. Minute ventilation was adjusted by varying the respiratory frequency, while tidal volume and FGF remained constant. This allowed for simultaneous measurements of PtcCO_2 and PETCO_2 to be compared with PaCO_2 over a range of carbon dioxide values, while each patient served as his or her own control. At each level of minute ventilation, the following end-tidal CO_2 values were achieved:

- Low – PETCO_2 28–30 mmHg
- Medium – PETCO_2 34–36 mmHg
- High – PETCO_2 40–42 mmHg

Measurements

Heart rate (HR) and mean arterial pressure (MAP) were measured using a Dinamapp 1846 SXP[®] non-invasive monitor. Oxygen saturation was recorded from a pulse oximeter, and temperature was measured using a nasopharyngeal temperature probe.

Transcutaneous CO_2 (PtcCO_2) measurements were recorded from the digital display of the Fastrac[®] PtcCO_2 monitor. Before each study, the device was calibrated

TABLE I Demographic data

Patients (<i>n</i>)	22
Age (yr)	37.2 ± 11.0
Sex (m/f)	5/17
Weight (kg)	65.1 ± 11.2
ASA (I/II/III)	14/6/2

TABLE II Haemodynamic and temperature values (mean ± SD)

	Low	Medium	High
HR (min ⁻¹)	69 ± 14	69 ± 13	70 ± 13
MAP (mmHg)	85 ± 13	87 ± 12	87 ± 12
SaO ₂ (%)	98.7 ± 0.8	98.7 ± 0.9	98.5 ± 0.8
Temperature (°C)	35.5 ± 0.4	35.5 ± 0.4	35.5 ± 0.4

Heart rate (HR), mean arterial pressure (MAP), oxygen saturation (SaO₂) and nasopharyngeal temperature for the three ranges of minute ventilation. Low = PETCO₂ 28–30 mmHg, Medium = PETCO₂ 34–36 mmHg, High = PETCO₂ 40–42 mmHg.

using a two-point self-calibration. The monitoring technique was standardized by applying a 2.5 cm probe to the patient's anterior chest. The probe was heated to 41°C to "arterialize" the skin capillary blood flow, and the monitor used an internal algorithm to compensate for the effects of the heated probe on CO₂ tension.

End-tidal CO₂ (PETCO₂) measurements were recorded from the on-line display of a mass spectrometer (System for Anesthetic and Respiratory Analysis[®], PPC, Missouri), using continuous sampling from a connector attached to the proximal end of the endotracheal tube. The mass spectrometer automatically performed a self-calibration every three hours using a guaranteed reference cylinder containing 5.1% CO₂ and 60% N₂O. Carbon dioxide and N₂O were "read" at mass charge ratios of 12 and 30 respectively, to prevent interference resulting from the identical molecular weights of these two gases. Using this system, the end-tidal CO₂ was determined from the latter portion of two successive respiratory waveforms. The capnograms were displayed on "Amber" monitors, and the measurements were recorded only when the CO₂ waveforms were normal.

Arterial CO₂ values were measured from blood gas samples obtained by radial artery puncture, and analyzed with a Corning 178 apparatus, which was calibrated each morning using a commercially available quality control blood gas analyzer (Ciba-Corning). Simultaneous measurements of PtcCO₂, PETCO₂ and PaCO₂ were recorded at each successive PETCO₂ level during maintenance of anaesthesia. Following each adjustment of ventilatory rate, five to ten minutes were allowed for stabilization of PETCO₂ and measurements were not recorded for an

additional ten minutes to ensure that both PtcCO₂ and PETCO₂ values had equilibrated at the new level of minute ventilation.

Statistical analysis

Linear regression analysis was performed to determine the correlation between each non-invasive method of CO₂ measurement and the arterial CO₂ over the entire range of carbon dioxide values. Student's unpaired *t* tests were also used to compare the PtcCO₂-PaCO₂ and PETCO₂-PaCO₂ gradients at each level of minute ventilation. Values are expressed as ranges and mean ± SD in the figures and text, with statistical significance assumed when *P* < 0.05.

Results

Twenty-two patients completed the study protocol, and the demographic data are shown in Table I. Surgical procedures included orthopaedic (*n* = 1), general surgery (*n* = 7), urological (*n* = 3) and gynaecological operations (*n* = 11), which had an average anaesthetic time of 2.1 ± 0.3 hr (range = 1.0–5.4 hr). The tracheas of all but two patients were extubated upon termination of surgery, and all patients recovered uneventfully.

Sixty-six data sets consisting of simultaneous measurements of PtcCO₂, PETCO₂ and PaCO₂ were obtained. In nine patients, a third set of measurements could not be completed due to termination of the surgical procedure prior to equilibration of CO₂ at the last step change in minute ventilation. The data sets were equally distributed amongst the three levels of minute ventilation. Heart rate, mean arterial pressure, and oxygen saturation were similar at the three measurement periods (Table II). Nasopharyngeal temperatures, which ranged from 34.8–36.3°C were also not different throughout the study period. The largest single decrease in temperature for any one patient was 0.5°C during the period of observation.

The relation of PtcCO₂ and PETCO₂ with respect to PaCO₂ values at all levels of minute ventilation is displayed in the scattergrams of Figures 1 and 2. The PtcCO₂ measurements tended to be slightly greater than the arterial CO₂ values, but correlated very closely with PaCO₂ as defined by the relationship $y = 0.904x + 6.36$ with a correlation coefficient of 0.92, *P* < 0.001 (Figure 1). The PETCO₂, which tended to underestimate the arterial CO₂ values, also showed a generally good correlation with PaCO₂ according to the relationship $y = 0.62x + 9.21$, with a correlation coefficient of 0.89, *P* < 0.01 (Figure 2).

The mean transcutaneous, end-tidal and arterial CO₂ values corresponding to the low, medium and high levels of minute ventilation are presented in Table III. From this data, the PtcCO₂-PaCO₂ and PETCO₂-PaCO₂ gradients were calculated, as displayed in Figure 3. This figure demonstrates that the PETCO₂-PaCO₂ gradients were larger




FIGURE 1 Transcutaneous CO₂ (PtcCO₂) vs arterial CO₂ (PaCO₂) measurements over the entire range of minute ventilation.




FIGURE 2 End-tidal CO₂ (PETCO₂) vs arterial CO₂ (PaCO₂) measurements over the entire range of minute ventilation.

TABLE III CO₂ values for the three levels of minute ventilation (mean ± SD)

	Low	Medium	High
PtcCO ₂ (mmHg)	36.2 ± 3.9	46.3 ± 3.8	53.2 ± 5.0
PETCO ₂ (mmHg)	28.2 ± 1.1	34.9 ± 1.2	42.1 ± 1.4
PaCO ₂ (mmHg)	33.5 ± 4.3	41.3 ± 3.2	51.3 ± 4.8

The mean ± SD transcutaneous (PtcCO₂), end-tidal (PETCO₂) and arterial (PaCO₂) carbon dioxide values for the three levels of minute ventilation (refer to legend of Table II for abbreviations).

than the PtcCO₂-PaCO₂ gradients at all three levels of minute ventilation ($P < 0.05$), with the end-tidal arterial gradient being largest at the high CO₂ levels ($P < 0.001$). Intraoperatively, the mean PtcCO₂-PaCO₂ gradient was only 2.3 ± 2.4 mmHg (range = 0.5–11.0 mmHg), while the mean PETCO₂-PaCO₂ gradient averaged 7.0 ± 3.1 mmHg (range = 2.0–21.0 mmHg).

Discussion

Continuous measurement of end-tidal carbon dioxide (PETCO₂) by either mass spectrometry or infrared capnometry has become standard practice for monitoring CO₂ concentrations of the end-tidal respiratory gases during general anaesthesia. However, one limitation of capnometry is an uncertainty of the magnitude of the end-tidal to arterial CO₂ gradient, which can vary between individuals. Most importantly, diseases which increase alveolar dead space will increase the end-tidal to arterial CO₂ gradient.^{4,6,9} It has also been shown that during anaesthesia and mechanical ventilation the PETCO₂-PaCO₂ gradient can be markedly increased even in individuals who deny any history of respiratory symptoms.¹⁰ This concern




FIGURE 3 The PtcCO₂-PaCO₂ and PETCO₂-PaCO₂ gradients at low, medium and high levels of minute ventilation, respectively. The transcutaneous-arterial gradients of CO₂ are consistently less than the end-tidal-arterial gradients ($P < 0.05$). For abbreviations refer to legend of Figure 1.

prompted us to evaluate a new transcutaneous CO₂ monitoring device in adult patients whose lungs were mechanically ventilated, as PtcCO₂ values are not influenced by factors which normally alter the end-tidal CO₂ measurements.

Our results show that the new Fastrac[™] CO₂ monitor provides a good correlation with PaCO₂ over a wide range of minute ventilation. The mean transcutaneous-arterial CO₂ gradient with the Fastrac[™] device was 2.3 ± 2.4 mmHg, over a range of 0.5–11 mmHg. The monitor

consistently provided a closer approximation to arterial PaCO₂ than did capnography. This was especially so at the higher PaCO₂ values, where the PETCO₂-PaCO₂ gradient was greatest. This observation is clinically important because it is in situations where carbon dioxide levels are rising that an accurate estimate of PaCO₂ is most essential, due to detrimental effects of hypoventilation and the ensuing hypercarbia and respiratory acidosis.⁹

These findings are consistent with results obtained from evaluation of other transcutaneous CO₂ monitors which have dual sensing electrodes (for carbon dioxide and oxygen). McEvedy *et al.* found that in neonates with severe lung disease, PtcCO₂ (measured with a Kontron Microgas transcutaneous monitor) provides a more accurate reflection of PaCO₂ ($r = 0.76$) than did PETCO₂, as measured with the Puritan-Bennett Datex capnometer ($r = 0.39$).¹¹ Others have shown that in neonates with respiratory distress syndrome, the Sensormedics cutaneous gas monitor provided a mean PtcCO₂-PaCO₂ gradient of 2.6 ± 7.0 mmHg, compared with a PETCO₂-PaCO₂ gradient of 9.6 ± 7.0 mmHg (Beckmann respiratory gas analyzer).¹² Another recent investigation in adults compared transcutaneous and end-tidal measurements of CO₂ during weaning from mechanical ventilation. In the study, Healey *et al.* demonstrated a 2.4 ± 5.7 mmHg PtcCO₂-PaCO₂ gradient with a TCM-20 Radiometer PtcCO₂ monitor, compared with a 7.5 ± 5.6 mmHg PETCO₂-PaCO₂ gradient when using the Lifespan 100 capnometer.¹³

The results of our study may seem somewhat surprising with respect to the relationship of the end-tidal to arterial CO₂ levels. The end-tidal values were less than arterial values by an average of 7 mmHg – an end-tidal to arterial difference which is somewhat greater than the 3–5 mmHg gradient usually reported for anaesthetized humans.^{2–4} As we had selected a healthy patient population for our study, we did not anticipate a PETCO₂-PaCO₂ gradient of this magnitude. However, it has been shown that the relationship between PETCO₂ and PaCO₂ is complex, and is actually determined by the slope of the “alveolar plateau” phase III of the CO₂ single breath test, and not simply alveolar dead space.¹⁴ Thus, several factors in addition to the preoperative respiratory status of the patient will influence the observed intraoperative CO₂ values. These include minute ventilation settings, the cardiovascular and volume status of the patient, and the effect of time. Raemer *et al.* showed that arterial to end-tidal CO₂ differences actually vary considerably during anaesthesia, even in a given patient with stable vital signs.⁶ Two of his patients had negative arterial to end-tidal CO₂ gradients, possibly due to the existence of areas of the lung with long time constants and a high PaCO₂.¹⁵ Another possible explanation for the 7.0 mmHg PETCO₂-PaCO₂ gradient we

demonstrated was that although all our patients denied symptoms of respiratory disease, seven of the 22 subjects had smoked at some time in the past. Fletcher has shown that even in the absence of respiratory symptoms, smoking increases the end-tidal to PaCO₂ difference during anaesthesia and artificial ventilation.¹⁰

Valid comparison of transcutaneous and end-tidal CO₂ measurements must take into consideration the effect of temperature on measured CO₂ values. In the current study, arterial blood gas samples were temperature-corrected to minimize the potential error related to differences between patients and within-patient temperature variation during the sampling periods. Temperature correction will produce a closer correlation of PETCO₂ and PaCO₂ values, but will increase the gradient between arterial and transcutaneous CO₂ measurements. This is because the PtcCO₂ monitor “arterializes” the capillary blood flow at the sensor site by heating the skin to 41° C, and then corrects the measured CO₂ value to 37° C rather than to the actual body temperature. Accordingly, the PtcCO₂-PaCO₂ gradient would be less than reported when using temperature-uncorrected arterial blood gas results, as has become common clinical practice.¹⁶

This study did not address the issue of the possible influence of decreased tissue perfusion on the accuracy of the PtcCO₂ monitor. In low cardiac output states, these devices may also have limitations, as does capnography, due to their dependence on local tissue perfusion.¹⁷ In such situations, it is probably best to rely on arterial blood gas sampling for accurate measurement of CO₂ levels and acid-base status.

We do not wish to infer from our results that the new transcutaneous CO₂ devices should replace capnography for routine respiratory monitoring in the perioperative setting. Limitations of this technology include the possibility of electrical drift of the signal, the requirement for regular maintenance and changes of the electrode membranes, and a small risk of thermal burns. There is no display of respiratory waveform. In contrast, capnography has the distinct advantage of providing a continuous CO₂ trace, in addition to providing breath-by-breath measurement of PETCO₂. The latter capability is crucial for allowing prompt verification of the correct position of the endotracheal tube, and for providing immediate warning of inadvertent disconnection from the ventilator.

Despite the limitations in transcutaneous CO₂ monitoring, the newer transcutaneous CO₂ devices may prove to be a valuable addition to capnography for patients who are suspected of having increased PETCO₂-PaCO₂ gradients, and in situations where continuous, non-invasive and precise control of the CO₂ level is desired. Examples might include individuals who have intracranial hypertension and those patients undergoing intracranial surgery.

The transcutaneous CO₂ monitor may also be useful in the recovery room or intensive care unit for managing non-intubated patients in whom respiratory depression or respiratory failure is a potential problem. Transcutaneous CO₂ monitoring may also be useful during weaning from mechanical ventilation, and may possibly facilitate a decrease in the number of arterial blood gas samples normally required in such situations. Finally, the newer monitors incorporate a pulse oximeter for measuring oxygen saturation.

This study evaluated the accuracy of a new transcutaneous carbon dioxide monitor for measuring P_{tc}CO₂ levels during general anaesthesia. The P_{tc}CO₂ values correlated very well with the measured PaCO₂. Furthermore, the transcutaneous-PaCO₂ gradients were consistently less than the end-tidal-PaCO₂ gradients over a wide range of minute ventilation settings. The enhanced accuracy, non-invasiveness, and simplicity in calibration and operation of the new transcutaneous CO₂ monitors may make these devices an important addition in the perioperative setting, particularly for patients who may have elevated P_{ET}CO₂-PaCO₂ gradients, and where continuous CO₂ monitoring is desired for non-intubated patients.

Acknowledgements

The authors thank the anaesthetists, surgeons and nurses of the operating room of the Ottawa General Hospital, whose assistance and patience permitted these studies. The support of the inhalational therapy staff of our institution is also gratefully acknowledged.

References

- 1 Lillie PE, Roberts JG. Carbon dioxide monitoring. *Anaesth Intensive Care* 1988; 16: 41-4.
- 2 Nunn JF, Hill DW. Respiratory dead space and arterial to end-tidal CO₂ tension difference in anaesthetized man. *J Appl Physiol* 1960; 15: 383-9.
- 3 Takki S, Aromaa U, Kauste A. The validity and usefulness of the end-tidal pCO₂ during anaesthesia. *Annals of Clinical Research* 1972; 4: 278-84.
- 4 Whitesell R, Asiddao C, Gollman D et al. Relationship between arterial and peak expired carbon dioxide pressure during anaesthesia and factors influencing the difference. *Anesth Analg* 1981; 60: 508-12.
- 5 McAslan TC. Automated respiratory gas monitoring of critically injured patients. *Crit Care Med* 1976; 4: 255-60.
- 6 Raemer DB, Francis D, Philip JH. Variations in PCO₂ between arterial and peak expired gas during anaesthesia. *Anesth Analg* 1983; 62: 1065-9.
- 7 Eberhard P, Mindt W, Schafer R. Cutaneous blood gas monitoring in the adult. *Crit Care Med* 1981; 9: 702-5.
- 8 Rafferty TD, Marrero O, Nardi D et al. Relationship between transcutaneous and arterial carbon dioxide tension in adult patients anaesthetized with nitrous oxide-fentanyl and nitrous oxide-enflurane. *Anesth Analg* 1981; 60: 504-7.
- 9 Nunn JF. Carbon dioxide. In: Nunn JF (Ed.). *Applied Respiratory Physiology*, 3rd ed, London: Butterworths Inc., 1987: 207-35.
- 10 Fletcher R. Smoking, age and the artificial end-tidal PCO₂ difference during anaesthesia and controlled ventilation. *Acta Anaesthesiol Scand* 1987; 31: 355-6.
- 11 McEvedy BA, McLeod ME, Mulera M, Kirpalini H, Lerman J. End-tidal, transcutaneous and arterial PCO₂ measurements in critically ill neonates: a comparative study. *Anesthesiology* 1988; 69: 112-6.
- 12 Hand I, Shepard E, Krauss A, Auld P. Discrepancies between transcutaneous and end-tidal carbon dioxide monitoring in the critically ill neonate with respiratory distress syndrome. *Crit Care Med* 1989; 17: 556-9.
- 13 Healey C, Fedullo A, Swinburne J, Wahl G. Comparison of non-invasive measurements of carbon dioxide tension during withdrawal from mechanical ventilation. 1987; 15: 764-8.
- 14 Fletcher R, Johnson B. Dead-space and the single breath test for carbon dioxide during anaesthesia and artificial ventilation. *Br J Anaesth* 1984; 56: 109-19.
- 15 Fletcher R, Malmkoist G, Niklasson L, Jonson B. On-line measurement of gas exchange during cardiac surgery. *Acta Anaesthesiol Scand* 1986; 30: 295-9.
- 16 Tinker JH, Campos JH. Pro: Blood gases should be corrected for temperature during hypothermic cardiopulmonary bypass: pH stat mode. *Journal of Cardiothoracic Anaesthesia* 1988; 2: 701-6.
- 17 Beran AV, Tolle CD, Huxtable RF. Cutaneous blood flow and its relationship to transcutaneous O₂/CO₂ measurements. *Crit Care Med* 1981; 9: 736-41.